Akcea shows off what No­var­tis missed and what Pfiz­er gained, of­fer­ing more de­tails on PhII car­dio da­ta

Back in Jan­u­ary Io­n­is spin­off Akcea teased, in two press re­leas­es is­sued one week apart, topline da­ta sug­gest­ing its two up-and-com­ing an­ti­sense oligonu­cleotides can sig­nif­i­cant­ly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER